ArticleGynecologic oncology reports2025
Rare leptomeningeal recurrence of mucinous ovarian carcinoma.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the fifth most common cause of cancer death in women and represents the deadliest of the gynecologic cancers. Despite treatment, 80 % of patients diagnosed with ovarian cancer will experience recurrence of disease within 18 months. Mucinous ovarian carcinoma represents an exceptionally rare subtype of ovarian cancer, comprising only 1-3 % of cases. Roughly 65-80 % of cases are diagnosed early at FIGO stage I with an excellent prognosis. However, for those diagnosed with advanced stage III-IV primary or recurrent disease, prognosis is extremely poor secondary to aggressive tumor biology and poor response to traditional platinum-based chemotherapy. Ovarian cancer recurrence most commonly arises secondary to transperitoneal and lymphatic spread of neoplastic cells. Central nervous system seeding, particularly leptomeningeal metastasis, is exceptionally rare with only palliative treatment options. Here, we describe a 44-year-old female with leptomeningeal recurrence remote from surgical treatment of stage IA mucinous ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.